Form 8-K - Current report:
SEC Accession No. 0001193125-24-255973
Filing Date
2024-11-12
Accepted
2024-11-12 16:16:53
Documents
15
Period of Report
2024-11-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d880680d8k.htm   iXBRL 8-K 22973
2 EX-99.1 d880680dex991.htm EX-99.1 173848
6 GRAPHIC g880680g1112183427447.jpg GRAPHIC 2975
  Complete submission text file 0001193125-24-255973.txt   343732

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA btmd-20241112.xsd EX-101.SCH 2833
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE btmd-20241112_lab.xml EX-101.LAB 17979
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE btmd-20241112_pre.xml EX-101.PRE 11247
17 EXTRACTED XBRL INSTANCE DOCUMENT d880680d8k_htm.xml XML 3639
Mailing Address 1875 W. WALNUT HILL LN #100 IRVING TX 75038
Business Address 1875 W. WALNUT HILL LN #100 IRVING TX 75038 972-486-9346
biote Corp. (Filer) CIK: 0001819253 (see all company filings)

EIN.: 851791125 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40128 | Film No.: 241448449
SIC: 2833 Medicinal Chemicals & Botanical Products
(CF Office: 03 Life Sciences)